Icariin promotes histone acetylation and attenuates post-stroke cognitive impairment in the central cholinergic circuits of mice

Wang, X.; Li, J.; Lai, Qi; Zang, Xuefeng; Zhang, S.-Y.; Wang, X.-Y.; Jin, Jie; Zhu, Xiaolei; Zhang, X.-B.; Wang, Z.-Y.; Xu, Yun

doi:10.1016/j.neuroscience.2012.12.074

Cited by 27 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dietary nucleotide citicoline may also improve recovery [101]. There are ongoing studies to explore the potential positive effect of phosphodiesterase-3, anti-inflammatory agents, BBB modulators, endothelin antagonist, flavonoids, immunosuppressive agents, peroxisome proliferator-activated receptor gamma antagonists, prostacylin, sympathomimetics, xanthine oxidase inhibitors, antidepressants, neurotrophic agents, gingko biloba extract Egb-761, and others [12, 102]. …”

Section: Pharmacological Interventions For Prevention Of Psdmentioning

confidence: 99%

Post-stroke dementia – a comprehensive review

Mijajlović

Pavlović

Brainin

et al. 2017

BMC Med

536

411

View full text Add to dashboard Cite

Post-stroke dementia (PSD) or post-stroke cognitive impairment (PSCI) may affect up to one third of stroke survivors. Various definitions of PSCI and PSD have been described. We propose PSD as a label for any dementia following stroke in temporal relation. Various tools are available to screen and assess cognition, with few PSD-specific instruments. Choice will depend on purpose of assessment, with differing instruments needed for brief screening (e.g., Montreal Cognitive Assessment) or diagnostic formulation (e.g., NINDS VCI battery). A comprehensive evaluation should include assessment of pre-stroke cognition (e.g., using Informant Questionnaire for Cognitive Decline in the Elderly), mood (e.g., using Hospital Anxiety and Depression Scale), and functional consequences of cognitive impairments (e.g., using modified Rankin Scale). A large number of biomarkers for PSD, including indicators for genetic polymorphisms, biomarkers in the cerebrospinal fluid and in the serum, inflammatory mediators, and peripheral microRNA profiles have been proposed. Currently, no specific biomarkers have been proven to robustly discriminate vulnerable patients (‘at risk brains’) from those with better prognosis or to discriminate Alzheimer’s disease dementia from PSD. Further, neuroimaging is an important diagnostic tool in PSD. The role of computerized tomography is limited to demonstrating type and location of the underlying primary lesion and indicating atrophy and severe white matter changes. Magnetic resonance imaging is the key neuroimaging modality and has high sensitivity and specificity for detecting pathological changes, including small vessel disease. Advanced multi-modal imaging includes diffusion tensor imaging for fiber tracking, by which changes in networks can be detected. Quantitative imaging of cerebral blood flow and metabolism by positron emission tomography can differentiate between vascular dementia and degenerative dementia and show the interaction between vascular and metabolic changes. Additionally, inflammatory changes after ischemia in the brain can be detected, which may play a role together with amyloid deposition in the development of PSD. Prevention of PSD can be achieved by prevention of stroke. As treatment strategies to inhibit the development and mitigate the course of PSD, lowering of blood pressure, statins, neuroprotective drugs, and anti-inflammatory agents have all been studied without convincing evidence of efficacy. Lifestyle interventions, physical activity, and cognitive training have been recently tested, but large controlled trials are still missing.

show abstract

Section: Pharmacological Interventions For Prevention Of Psdmentioning

confidence: 99%

Post-stroke dementia – a comprehensive review

Mijajlović

Pavlović

Brainin

et al. 2017

BMC Med

536

411

View full text Add to dashboard Cite

show abstract

“…In addition, icariin (30, 60, or 120 mg/kg, 4 weeks, po) also increased the expression of p‐CREB, the release of acetylcholine, and improved cognitive function in chronic stage of cerebral ischemia mouse model (Wang et al ., ). Therefore, EH and its components have contributed to synaptic plasticity in various models of brain disease.…”

Section: Synaptic Remodeling‐related Activitiesmentioning

confidence: 97%

Epimedii Herba: A Promising Herbal Medicine for Neuroplasticity

et al. 2017

View full text Add to dashboard Cite

Epimedii Herba (EH) is an herbal medicine originating from several plants of the genus Epimedium. It is a major therapeutic option for kidney yang deficiency syndrome, which is closely related to androgen hormones and also has been used to treat hemiplegia following a stroke in traditional medicine of Korea and PR China. To date, many clinical and basic researches of EH have shown the activities on functional recovery from brain diseases. Recently, neuroplasticity, which is the spontaneous reaction of the brain in response to diseases, has been shown to accelerate functional recovery. In addition, androgen hormones including testosterone are known to be the representative of neuroplasticity factors in the brain recovery processes. In this review, we described the neuro-pharmacological activities of EH, focusing on neuroplasticity. Thirty-three kinds of papers from MEDLINE/PubMed, EMBASE, and CNKI were identified and analyzed. We categorized the results into five types based on neuroplasticity mechanisms and presented the definition of each category and briefly described the results of these papers. Altogether, we can suggest that neuroplasticity is a novel viewpoint for guiding future brain research of EH and provide the evidence for the development of new clinical applications using EH in the treatment of brain diseases. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…Subcutaneous injection of D-galactose daily for 4 months can induce rat AD model with memory impairment and neuronal damage as neuronal arrangement disorder and acidophily degeneration. Orally administrated icariin (60 mg/kg/day) for 4 months can significantly improve the behavior of rats and the dysfunction of learning and memory, which is associated with upregulation of BDNF and its receptor TrkB expression in hippocampus [72]; and in natural aging rats, icariin exhibits similar functions [73].…”

Section: General Effects On Learning Ability and Memorymentioning

confidence: 99%

Potential therapeutic action of natural products from traditional Chinese medicine on Alzheimer's disease animal models targeting neurotrophic factors

Wei

2016

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells leads to memory loss and cognitive decline. To reduce the death rate and improve the biological activity of neurocytes, neurotrophic factors (NTFs) exhibit therapeutic effect on AD. However, therapeutic application of exogenous NTFs in treatment of AD is largely limited due to short half-life, poor stability, etc. Various extracts of traditional Chinese medicine (TCM) have been shown to exhibit therapeutic effects on AD, and some of these effects are associated with regulation on the expression of nerve growth factor, brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) and their associated receptors. This article reviews the progress on promotion of Panax ginseng, Rehmannia glutinosa Libosch., Epimedium, Polygala tenuifolia Willd, and seven other TCMs on secretion of NTFs during AD, with a view to preparation development and clinical application of these TCMs on AD.

show abstract

Icariin promotes histone acetylation and attenuates post-stroke cognitive impairment in the central cholinergic circuits of mice

Cited by 27 publications

References 37 publications

Post-stroke dementia – a comprehensive review

Post-stroke dementia – a comprehensive review

Epimedii Herba: A Promising Herbal Medicine for Neuroplasticity

Potential therapeutic action of natural products from traditional Chinese medicine on Alzheimer's disease animal models targeting neurotrophic factors

Contact Info

Product

Resources

About